丹黄祛瘀胶囊联合克林霉素治疗慢性盆腔炎的临床研究

目的观察丹黄祛瘀胶囊联合克林霉素治疗慢性盆腔炎的临床疗效。方法选取2015年1月—2016年1月上海市第一人民医院宝山分院进行治疗的慢性盆腔炎患者160例,随机分为对照组和治疗组,每组各80例。对照组患者口服盐酸克林霉素棕榈酸酯颗粒,2包/次,2次/d。治疗组患者在对照组的基础上口服丹黄祛瘀胶囊,4粒/次,3次/d。两组患者均连续治疗4周。治疗后,评价两组患者的临床疗效,同时比较治疗前后两组患者的炎症因子水平、平均包块直径以及不良反应。结果治疗后,对照组和治疗组的总有效率分别为81.25%、92.50%,两组总有效率比较差异有统计学意义(P0.05)。治疗后,两组患者的炎症因子水平均较治疗前显著降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组患者的炎症因子水平显著优于对照组患者,两组比较差异具有统计学意义(P0.05)。两组患者平均包块直径均较治疗前显著缩小,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组治疗后平均包块直径小于对照组,两组比较差异具有统计学意义(P0.05)。治疗组的不良反应发生率为12.50%,显著低于对照组患者的27.50%,两组不良反应发生率比较差异有统计学意义(P0.05)。结论丹黄祛瘀胶囊联合克林霉素治疗慢性盆腔炎的临床效果较好,可显著改善炎症因子水平和平均包块直径,且安全性较好,具有一定的临床推广应用价值。

Clinical study on Danhuang Quyu Capsule combined with clindamycin in treatment of chronic pelvic inflammation

Objective To observe the clinical efficacy of Danhuang Quyu Capsule combined with clindamycin in treatment of chronic pelvic inflammatory. Methods Patients (160 cases) with chronic pelvic inflammatory in Baoshan Branch of Shanghai First People''s Hospital from January 2015 to January 2016 were randomly divided into control and treatment groups, and each group had 80 cases. Patients in the control group were po administered with Clindamycin Palmitate Hydrochloride Flavored Granules, 2 bags/time, twice daily. Patients in the treatment group were po administered with Danhuang Quyu Capsule on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and inflammatory factors level, mean mass diameter, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.25% and 92.50%, respectively, and there was difference between two groups (P < 0.05). After treatment, the inflammatory factors in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the inflammatory factors in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The mean mass diameter in two groups was significantly reduced, and the difference was statistically significant in the same group (P < 0.05). And the mean mass diameter in the treatment group was significantly less than those in the control group, with significant difference between two groups (P < 0.05). The incidence of adverse reactions in the treatment group was 12.50%, which was significantly lower than 27.50% in the control group and there were differences between two groups (P < 0.05). Conclusion Danhuang Quyu Capsule combined with clindamycin has significant clinical efficacy in treatment of chronic pelvic inflammation, and can improve inflammatory factors level and mean mass diameter with good safety, which has a certain clinical application value.